Sagent Pharmaceuticals, Inc. Ampicillin for Injection, USP SDS Issue Date: Sep 29, 2014 SDS No.: SDS No.: SDS Version No.: SDS Version No.: R-SOP-009-F001 1 of 10

Section 1 - Identification

(a) **Product Identifier:** Ampicillin for Injection, USP

(b) Product Code: 25021-134, 25021-135, 25021-136, 25021-137, 25021-138

Common/Trade Name: Ampicillin Sodium

Chemical Name: Monosodium salt of $[2S-[2\alpha, 5\alpha, 6\beta(S^*)]]-6-$

[(aminophenylacetyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-

azabicyclo[3.2.0]heptane-2-carboxylic acid

Chemical Family: Anti-Infective

(c) **Product Use:** Pharmaceutical

Product Type: Regulated Prescription Drug

Container Information: Vials

(d) **Distributor:** Sagent Pharmaceuticals, Inc., 1901 N. Roselle Rd, Suite 700,

Schaumburg, IL 60195, 847-908-1600

(e) Emergency Telephone: 866-625-1618

Section 2 - Hazards Identification

(a) Classification: GHS Ratings

Respiratory Sensitization (Category 1)

Skin Sensitization (Category 1)

HMIS Rating

Health Hazard 3
Flammability 0
Physical Hazard 0

NFPA Rating

Health Hazard 3
Fire Hazard 0
Reactivity Hazard 0



| Sagent Pharmaceuticals, Inc. | | | | | |
|---------------------------------|---------------------|----------------------|-----------------------------|---------------|--|
| Ampicillin for Injection, USP | | | Safety Data Sheet (SDS) | | |
| SDS Issue Date: Sep 29, 2014 | SDS No.: SDS 030 | SDS Version No.: 3.0 | Form No.: R-SOP-009-F001 | Page: 2 of 10 | |

| (b) Signal Word, Hazard statement(s), Symbol(s), and/or Precautionary statement(s): | (c) Description of Hazards: |
|---|--|
| | - <u>Signal Word:</u> Danger |
| Hazard Statements: H315 H317 H334 | Causes Skin Irritation May cause an allergic skin reaction May cause allergy or asthma symptoms or breathing difficulties if inhaled |
| Precautionary Statements: | |
| P261 | - Avoid breathing dust/fume/gas/mist/vapours/spray |
| P272 | - Contaminated work clothing should not be allowed out of the workplace |
| P280 | - Wear protective gloves |
| P285 | - In case of inadequate ventilation wear respiratory protection |
| P302 + P352 | - IF ON SKIN: Wash with plenty of soap and water |
| P304 + P341 | - IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing |
| P321 | - Specific treatment (see supplemental first aid instructions on this label) |
| P333 + P313 | - If skin irritation or rash occurs: Get medical advice/attention |
| P342 + P311 | - If experiencing respiratory symptoms: Call a POISON CENTER or doctor/physician |
| P363 | - Wash contaminated clothes before reuse |
| P501 | Dispose of contents/container to an approved waste disposal plant |

(d) Unknown Acute Toxicity: N/A



| Sagent Pharmaceuticals, Inc. | | | | | | |
|--------------------------------|---------------------|------------------|-----------------------------|---------------|--|--|
| Ampicillin for Injection, USP | | | Safety Data Sheet (SDS) | | | |
| SDS Issue Date: Sep 29 2014 | SDS No.: SDS 030 | SDS Version No.: | Form No.: R-SOP-009-F001 | Page: 3 of 10 | | |

Section 3 – Composition / Information on Ingredients

| (a) Chemical Name | (b) Common Name / Synonym | % Composition or other measure | (c) CAS No. | (d) Impurities / Stabilizing Additives |
|--|---------------------------------|---|-------------|---|
| Monosodium salt of [2S-[2α, 5α, 6β(S*)]]-6- [(aminophenylacetyl)amino]- 3,3-dimethyl-7-oxo-4-thia-1- azabicyclo[3.2.0]heptane-2- carboxylic acid | Ampicillin Sodium | 100% | 69-52-3 | N/A |

Section 4 - First Aid Measures

Eye Exposure: Immediately rinse eyes with plenty of water for at least 15 minutes.

Keep eye wide open while rinsing. Seek medical advice.

Skin Exposure: Remove contaminated clothing immediately. Wash off immediately

with plenty of water for at least 15 minutes. Obtain medical attention if

skin reaction occurs.

Ingestion: Never attempt to induce vomiting. Flush mouth out with water

immediately. Seek medical attention.

Injection: In case of accidental injection, wash and disinfect area, set medical

attention.

Inhalation: Use appropriate personal protective equipment. Move to fresh air and

monitor breathing. If breathing becomes difficult, maintain ventilation,

give oxygen as appropriate and seek medical attention.

Notes to Physician: See patient package insert in shipping carton for complete information.

Section 5 – Fire-fighting Measures

(a) Extinguishing Media Water, carbon dioxide, dry chemical powder, polymer foam.

Water is recommended for fires involving packaging.

(b) Hazardous Dust clouds are potentially sensitive to ignition from electrostatic discharge especially if finely divided.

Combustion electrostatic discharge especially if finely divided. **Products:**

| | Sagent Pharmaceuticals, Inc. | | | | | | |
|--|---------------------------------|-------------------------|----------------------|-----------------------------|---------------------|--|--|
| | Ampicillin for Injection | Safety Data Sheet (SDS) | | | | | |
| | SDS Issue Date: Sep 29, 2014 | SDS No.: SDS 030 | SDS Version No.: 3.0 | Form No.: R-SOP-009-F001 | Page: 4 of 1 | | |

(c) **Special Protective** Carbon oxides (CO_x), nitrogen oxides (NO_x), sodium oxides,

4 of 10

sulfur oxides (SO_x) may be emitted upon thermal **Equipment /**

Precautions: decomposition.

Section 6 - Accidental Release Measures

Spill: Contain and collect spillage and place in container for disposal

> according to local regulations (See Section 13). Wipe surface area clean with soap and water. Avoid contact with strong oxidizing agents.

Release to Air: Prevent release to drains and waterways. Prevent release to the

environment.

Refer to local water authority. Drain disposal is not recommended; **Release to Water:**

refer to local, state, and federal disposal guidelines.

Section 7 - Handling and Storage

General Handling: When handling pharmaceutical products, avoid all contact and

inhalation of dust, fumes, mist and/or vapors associated with the

product. Keep away from sources of ignition.

Storage Conditions: Store at controlled room temperature between 20 to 25°C (68 to 77°F)

in the original container. Keep tightly closed.

Section 8 - Exposure Controls / Personal Protection

(a) Exposure Limits

| Compound | Issuer | Type | Exposure Limit |
|-------------------|--------|------|----------------|
| Ampicillin Sodium | OSHA | PEL | NE |
| | ACGIH | TLV | NE |
| | | STEL | NE |

(b) Engineering Controls

Ventilation: General room ventilation is usually satisfactory. Use local exhaust

ventilation if necessary.

| | | | 1 | ı |
|---|---|---|---|---|
| k | | ı | ı | ı |
| 1 | 1 | B | , | 1 |
| | | | | |

| Sagent Pharmaceuticals, Inc. | | | | | |
|---------------------------------|---------------------|----------------------|-----------------------------|----------------------|--|
| Ampicillin for Injection, USP | | | Safety Data Sheet (SDS) | | |
| SDS Issue Date: Sep 29, 2014 | SDS No.: SDS 030 | SDS Version No.: 3.0 | Form No.: R-SOP-009-F001 | Page: 5 of 10 | |

(c) Individual Protection Measures

| Respiratory Protection: | If respiratory protection is used, the type of protection will depend upon air concentration present, required protection factor as well as hazards, physical properties of substance present. |
|----------------------------------|--|
| Eye Protection: | Safety glasses with side shields or goggles are recommended. |
| Skin Protection: | Protect with disposable garments if direct skin contact is anticipated. |
| Other Protective Equipment: | Chemical resistant gloves. |
| Additional Exposure Precautions: | Wash hands and face before breaks and immediately after handling the product. |

Section 9 - Physical and Chemical Properties

| (a) | Appearance | White to off-white powder |
|--------------|--|---------------------------|
| (b) | Odor | Not established |
| (c) | Odor Threshold | None |
| (d) | рН | 8.0-10.0 |
| (e) | Melting Point: | 205 °C |
| (f) | Initial Boiling Point: | Not available |
| (g) | Flash Point | Not established |
| (h) | Evaporation Rate: | Not available |
| (i) | Flammability | Not available |
| (j) | Upper Lower Flammability or Explosion Limits | Not established |
| (k) | Vapor Pressure: | Not available |
| (l) | Vapor Density: | Not available |
| (m) | Relative Density | Not available |
| (n) | Solubility(ies) | Soluble in water |
| (0) | Partition Coefficient: n-octanol/water | N/A |
| (p) | Auto-ignition Temperature | Not established |
| (q) | Decomposition Temperature | N/A |
| (r) | Viscosity | N/A |



| Sagent Pharmaceuticals, Inc. | | | | | |
|---------------------------------|---------------------|-----------------------------|-----------------------------|----------------------|--|
| Ampicillin for Injection, USP | | | Safety Data Sheet (SDS) | | |
| SDS Issue Date: Sep 29, 2014 | SDS No.: SDS 030 | SDS Version No.: 3.0 | Form No.: R-SOP-009-F001 | Page: 6 of 10 | |

Section 10 - Stability and Reactivity

| (a) | Reactivity | Stable under normal conditions. |
|--------------|---|---|
| (b) | Chemical Stability | No hazardous polymerizations. |
| (c) | Possibility of Hazardous Reactions | See Section 10f |
| (d) | Conditions to Avoid | No conditions contributing to instability are known to exist. Avoid contact with strong oxidizing agents. |
| (e) | Incompatible Materials | Not available. |
| (f) | Hazardous Decomposition Products | Formed under fire conditions: Carbon oxides (CO_x) , nitrogen oxides (NO_x) , sodium oxides, sulfur oxides (SO_x) . |

Section 11 - Toxicological Information

| (a) | Likely Routes of Exposure | Inhalation, eye/skin contact, or ingestion | |
|-----|--|---|--|
| (b) | Symptoms related to the physical, chemical and toxicological characteristics | May cause respiratory tract, eye and skin irritation. May cause allergic respiratory and skin reaction. | |
| (c) | Delayed and immediate effects and also chronic effects from short and long term exposure | May cause sensitization by inhalation and skin contact. Irritating to eyes, respiratory system and skin. May cause allergic reaction in penicillin-sensitive individuals. | |

(d) Acute Toxicity

| Component | Type | Route | Species | Dosage |
|------------|------------------|-----------------|---------|-------------|
| Ampicillin | LD ₅₀ | Oral | Rat | 5314 mg/kg |
| Sodium | | | | |
| Ampicillin | LD ₅₀ | Intraperitoneal | Rat | 7400 mg/kg |
| Sodium | | _ | | |
| Ampicillin | LD ₅₀ | Subcutaneous | Rat | >5314 mg/kg |
| Sodium | | | | |

(e) Hazardous Chemical Listings

NTP: No IARC: No OSHA: No

| | 1 |
|---|---|
| L | • |
| | |

| Sagent Pharmaceuticals, Inc. | | | | |
|---------------------------------|---------------------|----------------------|-----------------------------|----------------------|
| Ampicillin for Injection, USP | | | Safety Data Sheet (SDS) | |
| SDS Issue Date: Sep 29, 2014 | SDS No.: SDS 030 | SDS Version No.: 3.0 | Form No.: R-SOP-009-F001 | Page: 7 of 10 |

Section 12 - Ecological Information

| (a) | Ecotoxicity No applicable ecological information found | |
|------------|---|---|
| (b) | Persistence and degradability | No applicable ecological information found. |
| (c) | Bioaccumulative potential | No applicable ecological information found. |
| (d) | Mobility in soil | No applicable ecological information found. |
| (e) | Other Adverse Effects | No applicable ecological information found. |

Section 13 - Disposal Considerations

Product

Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed professional waste disposal service to dispose of this material. Dissolve or mix the material with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.

Contaminated packaging

Dispose of as unused product.

Section 14 - Transport Information

| (a) | UN Number | Not regulated |
|--------------|--|---------------|
| (b) | UN Proper Shipping Name | Not regulated |
| (c) | Transport Hazard Class(es) | Not regulated |
| (d) | Packing Group | Not regulated |
| (e) | Environmental Hazards | Not regulated |
| (f) | Transport in bulk (according to Annex II of MARPOL 73/78 and the IBC Code) | Not regulated |
| (g) | Special Precautions | Not regulated |

DOT: Not dangerous goods

ICAO/IATA: Not dangerous goods

IMO: Not dangerous goods

Sagent Pharmaceuticals, Inc. Ampicillin for Injection, USP SDS Issue Date: Sep 29, 2014 SDS No.: SDS No.: SDS No.: SDS Version No.: R-SOP-009-F001 Page: R-SOP-009-F001 8 of 10

Section 15 - Regulatory Information

Below is selected regulatory information chosen primarily for possible Sagent usage. This section is not a complete analysis or reference to all applicable regulatory information. Please consider all applicable laws and regulations for your country/state.

U.S. Regulations:

TSCA - No

CERCLA - Not on this list

SARA 302 – Not on this list

SARA 313 - Not on this list

SARA 311/312: Acute Health Hazard

OSHA Substance Specific - No

Massachusetts Right to Know Components - No

Pennsylvania Right to Know Components – Yes

 $New\ Jersey\ Right\ to\ Know\ Components-Yes$

California Prop 65 Components – No

Section 16 - Other Information

As of the date of issuance, we are providing available information relevant to the handling of this material in the workplace. All information contained herein is offered with the good faith belief that it is accurate. THIS SAFETY DATA SHEET SHALL NOT BE DEEMED TO CREATE ANY WARRANTY OF ANY KIND (INCLUDING WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE). In the event of an adverse incident associated with this material, this safety data sheet is not intended to be a substitute for consultation with appropriately trained personnel. Nor is this safety data sheet intended to be a substitute for product literature which may accompany the finished product.

For additional information contact: Sagent Pharmaceuticals, Inc. 1901 N. Roselle Rd, Suite 700 Schaumburg, IL 60195 847-908-1600

Glossary: This glossary contains definitions of general terms used in SDSs. Not all of these Glossary Terms will apply to this SDS.

| ACGIH | American Conference of Governmental Industrial Hygienists | |
|-------|---|--|
| AICS | Australian Inventory of Chemical Substances | |
| AIHA | American Industrial Hygiene Association | |
| ANSI | American National Standards Institute | |



Sagent Pharmaceuticals, Inc. Ampicillin for Injection, USP SDS Issue Date: Sep 29, 2014 SDS No.: SDS Version No.: SDS Version No.: SDS Version No.: R-SOP-009-F001 Page: 9 of 10

| CAS Number | Chemical Abstract Service Registry Number |
|-------------|---|
| CERCLA | Comprehensive Environmental Response Compensation and Liability Act (of 1980) |
| CHAN | Chemical Hazard Alert Notice |
| CHEMTREC | Chemical Transportation Emergency Center |
| DOT | Department of Transportation |
| DSL | Domestic Substances List |
| ECHA | European Chemicals Agency |
| EINECS | European Inventory of Existing Commercial Chemical Substances |
| ELINCS | European List of Notified Chemical Substances |
| EPA | Environmental Protection Agency |
| GHS | Globally Harmonized System of Classification and Labelling of Chemicals |
| HEPA | High Efficiency Particulate Air (Filter) |
| HMIS | Hazardous Materials Identification System |
| IARC | International Agency for Research on Cancer |
| ICAO/IATA | International Civil Aviation Organization/International Air Transport Association |
| IMO | International Maritime Organization |
| KOW | Octanol/Water Partition Coefficient |
| LEL | Lower Explosive Limit |
| MSDS | Material Safety Data Sheet |
| MSHA | Mine Safety and Health Administration |
| NA | Not Applicable, except in Section 14 where NA = North America |
| NE NE | Not Established |
| NADA | New Animal Drug Application |
| NAIF | No Applicable Information Found |
| NCI | National Cancer Institute |
| NDSL | Non-Domestic Substances List |
| NFPA | National Fire Protection Association |
| NIOSH | National Institute for Occupational Safety and Health |
| NPDES | National Pollutant Discharge Elimination System |
| NOS | Not Otherwise Specified |
| NTP | National Toxicology Program |
| OSHA | Occupational Safety and Health Administration |
| OEL | Occupational Exposure Limit |
| PEL | Permissible Exposure Limit (OSHA) |
| RCRA | Resource Conservation and Recovery Act |
| | Resource Conservation and Recovery Act Reportable Quantity |
| RQ RTECS | Registry of Toxic Effects of Chemical Substances |
| SARA | Superfund Amendments and Reauthorization Act |
| SDS | Safety Data Sheet |
| STEL | Short Term Exposure Limit |
| TLV | Threshold Limit Value (ACGIH) |
| TPQ | Threshold Planning Quantity |
| _ ` | Toxic Substances Control Act |
| TSCA | |
| TWA | Time Weighted Average/8 Hours Unless Otherwise Noted |



| Sagent Pharmaceuticals, Inc. | | | | |
|---------------------------------|---------------------|----------------------|-----------------------------|-----------------------|
| Ampicillin for Injection, USP | | | Safety Data Sheet (SDS) | |
| SDS Issue Date: Sep 29, 2014 | SDS No.: SDS 030 | SDS Version No.: 3.0 | Form No.: R-SOP-009-F001 | Page: 10 of 10 |

| UEL | Upper Explosive Limit |
|-------|--|
| UN | United Nations |
| USP | United States Pharmacopeia |
| WEEL | Workplace Environmental Exposure Level (AIHA) |
| WHMIS | Workplace Hazardous Materials Information System |